Bullous skin lesions in a patient undergoing chronic hemodialysis

Porphyria cutanea tarda (PCT) is a vesiculobullous skin disorder characterized by a defect in heme biosynthesis. Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blister...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Seminars in dialysis 2010-01, Vol.23 (1), p.83-87
Hauptverfasser: Ryali, Madhavi E, Whittier, William L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 87
container_issue 1
container_start_page 83
container_title Seminars in dialysis
container_volume 23
creator Ryali, Madhavi E
Whittier, William L
description Porphyria cutanea tarda (PCT) is a vesiculobullous skin disorder characterized by a defect in heme biosynthesis. Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blistering that is characteristic of this disease. The majority of cases of PCT are associated with acquired deficiencies of the enzyme URO-D, secondary to hepatic injury precipitated by medications or infections. Less commonly, PCT has been documented in patients with end-stage renal disease. The pathogenesis of PCT in long-term hemodialysis (HD) has been attributed to many factors, but the following mechanisms have been implicated: (i) decreased hepatic URO-D activity due to suppressive effects of iron and other hepatotoxins and (ii) poor porphyrin clearance by renal replacement therapies. We report a case of PCT that developed in a patient on maintenance HD for 4 years. He had a history of hepatitis C and evidence of iron overload. However, as the patient was anemic, therapeutic phlebotomy was problematic and therefore erythrocyte-stimulating agents were maximized to mobilize iron stores and allow phlebotomy. With this treatment, the patient's skin lesions improved in conjunction with decreasing ferritin levels.
doi_str_mv 10.1111/j.1525-139X.2009.00672.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733806036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733806036</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-a081edb7e4f430fae27682b9a523ce821ce460842875bb47a2a1af01a5835b43</originalsourceid><addsrcrecordid>eNo9T0tPwzAYi5AQG4O_gHLj1PLl0SY9jomXNInLDtyqpP26ZaRpaVqJ_XsqMfDFlmxZNiGUQcpmPBxTlvEsYaL4SDlAkQLkiqffF2T5byzIdYxHACa4kldkwUEIpjksyfpx8r6bIo2fLlCP0XUh0lka2pvRYRjpFGoc9p0Le1odhi64ih6w7Wpn_Cm6eEMuG-Mj3p55RXbPT7vNa7J9f3nbrLdJzxmMiQHNsLYKZSMFNAa5yjW3hcm4qFBzVqHMQUuuVWatVIYbZhpgJtMis1KsyP1vbT90XxPGsWxdrNB7E3DeXyohNOQg8jl5d05OtsW67AfXmuFU_p0WP255WQs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733806036</pqid></control><display><type>article</type><title>Bullous skin lesions in a patient undergoing chronic hemodialysis</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Ryali, Madhavi E ; Whittier, William L</creator><creatorcontrib>Ryali, Madhavi E ; Whittier, William L</creatorcontrib><description>Porphyria cutanea tarda (PCT) is a vesiculobullous skin disorder characterized by a defect in heme biosynthesis. Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blistering that is characteristic of this disease. The majority of cases of PCT are associated with acquired deficiencies of the enzyme URO-D, secondary to hepatic injury precipitated by medications or infections. Less commonly, PCT has been documented in patients with end-stage renal disease. The pathogenesis of PCT in long-term hemodialysis (HD) has been attributed to many factors, but the following mechanisms have been implicated: (i) decreased hepatic URO-D activity due to suppressive effects of iron and other hepatotoxins and (ii) poor porphyrin clearance by renal replacement therapies. We report a case of PCT that developed in a patient on maintenance HD for 4 years. He had a history of hepatitis C and evidence of iron overload. However, as the patient was anemic, therapeutic phlebotomy was problematic and therefore erythrocyte-stimulating agents were maximized to mobilize iron stores and allow phlebotomy. With this treatment, the patient's skin lesions improved in conjunction with decreasing ferritin levels.</description><identifier>EISSN: 1525-139X</identifier><identifier>DOI: 10.1111/j.1525-139X.2009.00672.x</identifier><identifier>PMID: 20331820</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Humans ; Male ; Porphyria Cutanea Tarda - etiology ; Renal Dialysis - adverse effects ; Skin Diseases, Vesiculobullous - etiology</subject><ispartof>Seminars in dialysis, 2010-01, Vol.23 (1), p.83-87</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20331820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ryali, Madhavi E</creatorcontrib><creatorcontrib>Whittier, William L</creatorcontrib><title>Bullous skin lesions in a patient undergoing chronic hemodialysis</title><title>Seminars in dialysis</title><addtitle>Semin Dial</addtitle><description>Porphyria cutanea tarda (PCT) is a vesiculobullous skin disorder characterized by a defect in heme biosynthesis. Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blistering that is characteristic of this disease. The majority of cases of PCT are associated with acquired deficiencies of the enzyme URO-D, secondary to hepatic injury precipitated by medications or infections. Less commonly, PCT has been documented in patients with end-stage renal disease. The pathogenesis of PCT in long-term hemodialysis (HD) has been attributed to many factors, but the following mechanisms have been implicated: (i) decreased hepatic URO-D activity due to suppressive effects of iron and other hepatotoxins and (ii) poor porphyrin clearance by renal replacement therapies. We report a case of PCT that developed in a patient on maintenance HD for 4 years. He had a history of hepatitis C and evidence of iron overload. However, as the patient was anemic, therapeutic phlebotomy was problematic and therefore erythrocyte-stimulating agents were maximized to mobilize iron stores and allow phlebotomy. With this treatment, the patient's skin lesions improved in conjunction with decreasing ferritin levels.</description><subject>Adult</subject><subject>Humans</subject><subject>Male</subject><subject>Porphyria Cutanea Tarda - etiology</subject><subject>Renal Dialysis - adverse effects</subject><subject>Skin Diseases, Vesiculobullous - etiology</subject><issn>1525-139X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9T0tPwzAYi5AQG4O_gHLj1PLl0SY9jomXNInLDtyqpP26ZaRpaVqJ_XsqMfDFlmxZNiGUQcpmPBxTlvEsYaL4SDlAkQLkiqffF2T5byzIdYxHACa4kldkwUEIpjksyfpx8r6bIo2fLlCP0XUh0lka2pvRYRjpFGoc9p0Le1odhi64ih6w7Wpn_Cm6eEMuG-Mj3p55RXbPT7vNa7J9f3nbrLdJzxmMiQHNsLYKZSMFNAa5yjW3hcm4qFBzVqHMQUuuVWatVIYbZhpgJtMis1KsyP1vbT90XxPGsWxdrNB7E3DeXyohNOQg8jl5d05OtsW67AfXmuFU_p0WP255WQs</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>Ryali, Madhavi E</creator><creator>Whittier, William L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201001</creationdate><title>Bullous skin lesions in a patient undergoing chronic hemodialysis</title><author>Ryali, Madhavi E ; Whittier, William L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-a081edb7e4f430fae27682b9a523ce821ce460842875bb47a2a1af01a5835b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Humans</topic><topic>Male</topic><topic>Porphyria Cutanea Tarda - etiology</topic><topic>Renal Dialysis - adverse effects</topic><topic>Skin Diseases, Vesiculobullous - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ryali, Madhavi E</creatorcontrib><creatorcontrib>Whittier, William L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ryali, Madhavi E</au><au>Whittier, William L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bullous skin lesions in a patient undergoing chronic hemodialysis</atitle><jtitle>Seminars in dialysis</jtitle><addtitle>Semin Dial</addtitle><date>2010-01</date><risdate>2010</risdate><volume>23</volume><issue>1</issue><spage>83</spage><epage>87</epage><pages>83-87</pages><eissn>1525-139X</eissn><abstract>Porphyria cutanea tarda (PCT) is a vesiculobullous skin disorder characterized by a defect in heme biosynthesis. Reduced activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D) results in accumulation of photosensitive porphyrins; this ultimately leads to the skin fragility and blistering that is characteristic of this disease. The majority of cases of PCT are associated with acquired deficiencies of the enzyme URO-D, secondary to hepatic injury precipitated by medications or infections. Less commonly, PCT has been documented in patients with end-stage renal disease. The pathogenesis of PCT in long-term hemodialysis (HD) has been attributed to many factors, but the following mechanisms have been implicated: (i) decreased hepatic URO-D activity due to suppressive effects of iron and other hepatotoxins and (ii) poor porphyrin clearance by renal replacement therapies. We report a case of PCT that developed in a patient on maintenance HD for 4 years. He had a history of hepatitis C and evidence of iron overload. However, as the patient was anemic, therapeutic phlebotomy was problematic and therefore erythrocyte-stimulating agents were maximized to mobilize iron stores and allow phlebotomy. With this treatment, the patient's skin lesions improved in conjunction with decreasing ferritin levels.</abstract><cop>United States</cop><pmid>20331820</pmid><doi>10.1111/j.1525-139X.2009.00672.x</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1525-139X
ispartof Seminars in dialysis, 2010-01, Vol.23 (1), p.83-87
issn 1525-139X
language eng
recordid cdi_proquest_miscellaneous_733806036
source MEDLINE; Wiley Journals
subjects Adult
Humans
Male
Porphyria Cutanea Tarda - etiology
Renal Dialysis - adverse effects
Skin Diseases, Vesiculobullous - etiology
title Bullous skin lesions in a patient undergoing chronic hemodialysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A11%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bullous%20skin%20lesions%20in%20a%20patient%20undergoing%20chronic%20hemodialysis&rft.jtitle=Seminars%20in%20dialysis&rft.au=Ryali,%20Madhavi%20E&rft.date=2010-01&rft.volume=23&rft.issue=1&rft.spage=83&rft.epage=87&rft.pages=83-87&rft.eissn=1525-139X&rft_id=info:doi/10.1111/j.1525-139X.2009.00672.x&rft_dat=%3Cproquest_pubme%3E733806036%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733806036&rft_id=info:pmid/20331820&rfr_iscdi=true